IgA anti-β2-glycoprotein I as an independent risk factor in acute venous thromboembolism.
Venous thromboembolism (VTE) is the third most common cause of cardiovascular death. Primary Antiphospholipid Syndrome (P-APS) is a chronic systemic autoimmune disorder characterized by thrombotic events and/or obstetric complications in patients carrying antiphospholipid antibodies (aPL) without autoimmune pathology. The prevalence of primary antiphospholipid syndrome (P-APS) in patients with VTE is approximately 9%. However, few studies have evaluated non-criteria antiphospholipid antibodies in the acute phase of VTE.
To assess the role of criteria and non-criteria antiphospholipid antibodies in patients with acute VTE.
A cohort of 181 patients with VTE was followed for 2 years. An age-matched control group of 181 healthy individuals was included for comparison.
Criteria aPL were detected in 8.8% of patients, whereas non-criteria aPL were present in 23.8%. Criteria aPL were independently associated with overall VTE (OR 7.09, p=0.021) and unprovoked VTE (OR 4.61, p=0.021). IgA anti-Beta2 Glycoprotein-1 antibodies (aB2GP1), detected in 16% of patients, were independently associated with VTE (OR 4.31, p=0.014) and unprovoked VTE (OR 3.78, p=0.006). Furthermore, IgA aB2GP1 positivity was also associated with more severe clinical presentation, defined by a Pulmonary Embolism Severity Index scale ≥3 (OR 3.13; p=0.048), and with the development of chronic thromboembolic pulmonary hypertension (OR 5.7; p=0.008).
IgA aB2GP1 antibodies are independently associated with VTE, particularly unprovoked VTE, and with both severe pulmonary embolism, and subsequent chronic thromboembolic pulmonary hypertension.
To assess the role of criteria and non-criteria antiphospholipid antibodies in patients with acute VTE.
A cohort of 181 patients with VTE was followed for 2 years. An age-matched control group of 181 healthy individuals was included for comparison.
Criteria aPL were detected in 8.8% of patients, whereas non-criteria aPL were present in 23.8%. Criteria aPL were independently associated with overall VTE (OR 7.09, p=0.021) and unprovoked VTE (OR 4.61, p=0.021). IgA anti-Beta2 Glycoprotein-1 antibodies (aB2GP1), detected in 16% of patients, were independently associated with VTE (OR 4.31, p=0.014) and unprovoked VTE (OR 3.78, p=0.006). Furthermore, IgA aB2GP1 positivity was also associated with more severe clinical presentation, defined by a Pulmonary Embolism Severity Index scale ≥3 (OR 3.13; p=0.048), and with the development of chronic thromboembolic pulmonary hypertension (OR 5.7; p=0.008).
IgA aB2GP1 antibodies are independently associated with VTE, particularly unprovoked VTE, and with both severe pulmonary embolism, and subsequent chronic thromboembolic pulmonary hypertension.
Authors
Diaz-Simon Diaz-Simon, Lalueza Lalueza, Serrano Serrano, Pleguezuelo Pleguezuelo, Cabrera-Marante Cabrera-Marante, Lora Lora, Diaz-Pedroche Diaz-Pedroche, Gomez-Cuervo Gomez-Cuervo, Perez-Jaicoste Perez-Jaicoste, Garcinuño Garcinuño, Naranjo Naranjo, Martinez-Chamorro Martinez-Chamorro, Revilla-Ostolaza Revilla-Ostolaza, Paz-Artal Paz-Artal, Lumbreras-Bermejo Lumbreras-Bermejo, Serrano Serrano
View on Pubmed